NMOSD Management with New FDA-approved Agents to Reduce Relapse and Hospitalization Rates

Author(s):

Key Takeaways

Early and aggressive treatment strategies are crucial in reducing NMOSD relapse and hospitalization rates.
Personalized treatment plans should incorporate new therapeutic agents and monitoring protocols for optimal outcomes.
Collaboration with multidisciplinary teams and patient education are essential in effective NMOSD management.
Sharing insights and experiences with peers enhances understanding and implementation of management strategies.

A panelist discusses how neurologists can adapt their NMOSD management strategies based on recent findings about relapse and hospitalization rates, sharing practical advice and clinical experience for optimizing patient outcomes.

EP: 1.Current Treatment Landscape of AQP4-IgG+ NMOSD and Considerations on Relapse Rates

EP: 2.Shared Decision-making for Selection of FDA-approved Therapies for NMOSD

EP: 3.Implications of Relapse and Hospitalization Rates with Rituximab Use in NMOSD Management

Now Viewing

EP: 4.NMOSD Management with New FDA-approved Agents to Reduce Relapse and Hospitalization Rates

Video content above is prompted by the following:

In your clinical practice, how have you adapted your approach to NMOSD management in light of these recent findings on relapse and hospitalization rates?
What advice do you have for other neurologists in managing patients with NMOSD and reducing relapse/hospitalization rates?